Grossi Federico

About Grossi Federico

Dr. Federico Grossi, M.D., Ph.D., served as Chief Medical Officer at Apellis Pharmaceuticals, Inc., a Nasdaq-listed biopharmaceutical company focused on complement science. Company filings show that he joined Apellis in 2010 as Clinical Research Director, was promoted to Vice President of Clinical Development in October 2014, became Executive Vice President of Clinical Development in October 2017, and was appointed Chief Medical Officer in April 2019. Apellis later disclosed that he would leave the company in early 2023, after helping with the transition and preparations tied to major clinical and launch activities. ([investors.apellis.com](https://investors.apellis.com/node/9761/html?utm_source=openai)) His Apellis career reflects deep experience in clinical development, medical strategy, and late-stage readiness for innovative therapies. Public company disclosures indicate that he was involved in the preparations for the potential launch of pegcetacoplan for geographic atrophy, a significant milestone for Apellis and an important step in the company’s ophthalmology portfolio. His progression from clinical research leadership to the top medical role suggests a blend of scientific expertise and operational leadership, particularly in programs requiring close coordination across research, clinical, regulatory, and commercial functions. ([investors.apellis.com](https://investors.apellis.com/news-releases/news-release-details/apellis-appoints-leading-retina-specialist-dr-caroline-baumal?utm_source=openai)) Before Apellis, Grossi held senior clinical-development roles at Potentia Pharmaceuticals, Inc., where he served as Clinical Research Director from 2006 to April 2010 and later as Executive Vice President from 2013 to 2014. These earlier positions show a sustained background in biotech drug development and increasing responsibility over clinical programs. Overall, his professional profile is characterized by medical and scientific training, leadership in clinical development, and experience advancing therapies for serious diseases. The publicly available information supports a strong, generally biopharmaceutical-oriented biography, while more specific details about individual decisions or additional companies are not clearly documented in the sources reviewed. ([investors.apellis.com](https://investors.apellis.com/node/7001/html?utm_source=openai))